For herbal brands, the in-house vs contract manufacturing decision is one of the highest-stakes structural calls you'll make in the first three years of operation. The wrong model locks up cash and slows launches. It also forces a costly migration of formulas, suppliers, and compliance records two years later. The right model gets product on shelves with margin intact and your team focused on demand generation. This post lays out the trade-offs honestly. We cover what each model actually costs, where each model breaks, and the signals that point toward one path.
Key Takeaways
- The real cost of in-house herbal manufacturing is GMP infrastructure and personnel, not the equipment line.
- Contract manufacturing converts capital expenditure into per-batch unit cost, freeing cash for marketing and SKU development.
- Health Canada site licensing applies to whoever produces the product — not whoever owns the brand.
- Most successful Canadian herbal brands under $5M revenue use contract manufacturing exclusively.
- Hybrid models (contract base + in-house custom) appear after $3–5M revenue but add regulatory complexity, not subtract it.
What "In-House" Actually Means for an Herbal Brand
The in-house vs contract manufacturing decision for herbal brands begins with one regulatory fact: in Canada, the entity producing the product must hold a Health Canada site licence under the Natural Health Products Regulations. That bar is non-negotiable. It's not a commercial kitchen, not a co-packing arrangement under someone else's licence, and not a private workshop. Owning production means owning the licence, the SOPs, and the liability.
Here's what that means in practice. Floor plan approval, quarantine zones, environmental controls, written SOPs, trained QA personnel, and a documented stability program — all required. The capital line item brand owners focus on — extraction tanks, filtration, filling lines — is rarely the bottleneck. The bottleneck is GMP compliance and the operational team to maintain it.
A brand pursuing in-house manufacturing typically needs 12–18 months from build-out to first commercial batch. Capital expenditure runs $400K–$1.2M depending on output target. A dedicated QA lead costs $90K–$130K. Ongoing investment in batch records, testing, and supplier qualification is constant. None of that is optional under a site licence.
Worth understanding before you proceed: the licence holder bears full regulatory liability for every batch. That liability does not transfer to ingredient suppliers, packaging vendors, or downstream retailers. It sits with the manufacturer.
Contract Manufacturing — The Trade-offs for Herbal Brands
Contract manufacturing inverts the cost structure that in-house production demands. Capital expenditure becomes operational expenditure, expressed as a per-bottle or per-batch unit cost. The manufacturer holds the site licence, runs the QA program, and is the named party in any Health Canada inspection of the production process. Your brand owns the formula, the artwork, the IP, and the customer relationship. Everything that compounds in value over time stays with the brand.
In our experience, brands that choose contract manufacturing in their first 24 months outperform on two metrics. Those are time-to-launch and SKU velocity. The first SKU goes live in 8–14 weeks rather than 12–18 months. Adding a second or third formulation doesn't require new infrastructure — just a new BOM and an updated NPN submission.
The practical trade-off: you don't control the production schedule directly. A contract manufacturer is allocating tank time, fill line slots, and QA review capacity across multiple brands. Lead times become a planning constraint, not a button you press. Brands that grasp this early build forecasts that pace with manufacturing reality. For specifics, see our piece on flexible-MOQ manufacturing in Canada.
Brands that don't grasp the scheduling reality tend to learn during their first stockout. The fix is forecasting discipline, not production control.
Cost Comparison: In-House vs Contract Manufacturing for Herbal Brands
A direct cost comparison between in-house and contract manufacturing only makes sense at projected annual volume. Below ~50,000 finished units per year, contract manufacturing is almost always lower total cost. Above ~200,000 units per year of a stable formulation, the math favours in-house. But only if the brand can fully utilize the facility.
The middle range is where most brands actually live. That's where the decision turns on capital availability, regulatory bandwidth, and SKU complexity — not unit economics alone. Specifically, a brand with 8 SKUs at 30K–80K units each will not benefit from in-house at any realistic utilization curve.
Here's a rough sketch for a 100mL tincture, all-in cost including bottle, label, cap, and herbal ingredients:
The third row is where in-house brands quietly bleed cash. Idle capacity is expensive. Amortized GMP overhead doesn't scale down when sales lag forecast. For a deeper view at your formulation, our tincture calculator models per-bottle cost across volume tiers.
When In-House Makes Sense — and When It Doesn't
In-house manufacturing is the right call for a narrow set of herbal brands. Specifically: a single hero SKU with $2M+ annual revenue and continued growth. Or a proprietary process where IP protection requires production control. Sometimes a geographic or supply-chain rationale — for instance, traceability claims that genuinely need vertical integration. Above all, a founding team with prior GMP operations experience.
In contrast, in-house is the wrong call — even at scale — under several conditions. The product line is broad and changing (10+ SKUs, frequent reformulations). Capital is needed for marketing and distribution rather than infrastructure. Your team has no manufacturing background and is hiring in cold. Or regulatory bandwidth is already stretched across other obligations.
This is where most brands run into trouble. The instinct to "own production" feels right but routes capital away from activities that actually grow the brand. Those are distribution, brand building, and customer acquisition. As a result, brands that defer the in-house decision until forced into it outperform brands that pursue it on instinct.
The practical implication: the in-house question is a milestone decision, not a launch decision. Defer it until volume and SKU stability make the math undeniable.
Hybrid Models — Common in Practice, Not Simpler
After $3–5M in annual revenue, some herbal brands shift to a hybrid model. Contract manufacturing for the volume catalogue, in-house for limited-release or custom batches. The hybrid has surface appeal — production control on signature SKUs, contract leverage on the rest. However, it introduces real regulatory complexity that brand owners frequently underestimate.
Both facilities require their own site licence. Both require their own QA program, their own SOPs, their own stability data. Documentation must be reconciled across two production records. Inspections happen at each licensed site independently. A finding at one does not automatically cascade, but the regulator will ask how QA systems are aligned.
Here's how we handle it. Brands that contract with us for the volume catalogue while running their own facility for limited runs use shared specs and supplier lists wherever possible. In addition, we align stability and testing protocols across both sites. That reduces the chance of one inspection finding raising questions about the other site.
The short version: hybrid is workable above a certain scale, but it is not simpler than choosing one model and committing to it.
Decision Framework: In-House vs Contract Manufacturing for Herbal Brands
For herbal brands working through this question now, the framework comes down to four inputs. Annual volume, SKU count, capital availability, and regulatory bandwidth. Score each on a low/medium/high scale, then read the result.
High volume, low SKU count, high capital, and high regulatory bandwidth points toward in-house. Low or medium volume, high SKU count, capital constrained, and thin regulatory bandwidth points toward contract. Anything in between defaults to contract. That holds until at least two of the four inputs shift decisively.
Furthermore, brand owners forget that this decision is reversible. Moving from contract to in-house at $5M revenue is hard but routine. Moving back to contract after sinking $1M into facility build-out is a write-down. The asymmetry favours starting on contract.
If you're at the decision point, our manufacturing team can walk through unit economics at your projected volume. Our how to choose an herbal contract manufacturer guide also covers evaluation criteria buyers often miss.
The in-house vs contract manufacturing decision for an herbal brand is not a one-time answer. It's a model that should evolve with revenue, SKU count, and regulatory bandwidth. Most brands launch on contract and grow on contract. They only revisit the question after passing $3M in revenue with a stable hero product. Some never need to revisit it. The contract model continues to outperform on cash efficiency and SKU flexibility well into the eight-figure range. Whichever way you're leaning, run the numbers honestly against your projected utilization.
Published: May 21, 2026